- Home
- Companies
- switzerland
- phenotyping
Show results for
Refine by
Phenotyping Suppliers In Switzerland
14 companies found
based inZürich, SWITZERLAND
BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between ...
BC|RQUEST as a private service enables availability queries and aggregated analysis on biobanks or internal data silos through a simple web interface for query building and analysis creation. Additionally, BC|RQUEST gives biobanks tools to manage ...
based inGeneve, SWITZERLAND
STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have ...
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches ...
based inLausanne, SWITZERLAND
AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases ...
People with HLH usually develop symptoms within the first months or years of life. Symptoms may include fever, enlarged liver or spleen, cytopenia (decreased number of blood cells), and neurological abnormalities. All forms of HLH, including cases ...
based inBiel/Bienne, SWITZERLAND
We work for a world where regenerative medicine is accessible to everyone. MimiX develops and commercializes a proprietary technology to foster scientific discoveries and clinical translation. MimiX biotherapeutics introduces Sound Induced ...
Biologicals – Cells, spheroids, organoids- or non-biological particles are dispersed in a hydrogel precursor and loaded in the SIM carrier. A vertical vibration generated with sound is applied, and a pattern is generated within seconds. ...
based inRotkreuz, SWITZERLAND
Roche Diagnostics is a division of Roche. We develop and integrate diagnostic solutions that address the challenges of today and anticipate the needs of tomorrow. In more than 100 countries, we offer the industry’s most comprehensive in vitro ...
GenMark’s ePlex® Blood-Culture Identification (BCID) Panels provide broad coverage of organisms that can lead to sepsis along with their resistance genes. This broad coverage means that about 95% of currently identified bloodstream ...
based inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...
based inSanta Clara, CALIFORNIA (USA)
For more than 40 years, Agilent Technologies has been the leading provider of solutions for the detection, identification, and characterization of chemical and biological compounds. From environmental testing to semiconductor manufacturing, ...
Cytation 5 combines automated microscopy and conventional microplate detection in a configurable, upgradable platform. The microscopy module offers up to 60x magnification in fluorescence, brightfield, high contrast brightfield, color brightfield, ...
based inSchlieren, SWITZERLAND
The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base incl. BERNINA BioInvest, Redalpine, and UZH Life Sciences ...
EraCal’s platform enables unbiased and large-scale in vivo drug discovery in zebrafish larvae. The journal Science Advances published part of EraCal’s translational proof of concept. Such phenotypic strategies are ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the immune system to recognize tumor cells ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
Test efficacy of anti-NASH drugs in an advanced 3D human liver disease model. The InSphero 3D InSight™ Human Liver NASH Model consists of an advanced microtissue co-culture of healthy primary human liver cells combined with specially ...
based inBasel, SWITZERLAND
Since its founding in 1997, Genedata has been supporting the transformation of biopharma R&D. Today, the Genedata Biopharma Platform digitalizes biopharmaceutical R&D processes, streamlining the entire R&D workflow to increase throughput and improve ...
based inGiesbeek, NETHERLANDS
Royal Eijkelkamp makes a difference worldwide by developing, producing and delivering solutions for soil and water research. Our innovative solutions, coupled with the knowledge and expertise of our soil and water specialists at Royal Eijkelkamp, ...
based inSchlieren, SWITZERLAND
Elthera AG is a Swiss biopharmaceutical company founded in 2016 by experienced Pharma and Biotech executives with the goal of developing proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing ...
L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors show a highly malignant and invasive ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Most rare and inherited diseases have a neurological component, likely because more than 80% of human genes are expressed in the brain.1 Neurological disorders are multifactorial and heterogeneous, meaning that their genetic basis is often poorly ...